If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient option to address episodes of fluid buildup at home, benefiting patients, providers and payorsPDUFA target action date of July 26, 2026 WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administrat ...

Core Insights - CHC Navigation has formed a strategic partnership with CNH Industrial to integrate precision agriculture technologies into CNH's FP FleetPro aftermarket kits, enhancing accessibility for farmers [2][3][4] Group 1: Partnership Overview - The collaboration aims to incorporate CHCNAV's high-precision guidance systems into CNH's FP FleetPro product line, making precision farming tools more accessible and reliable for a broader audience [2][3] - The FP FleetPro guidance kits are designed to be cost-effective and easy to use, allowing installation across various types of agricultural equipment without the need for full fleet replacement [3][4] Group 2: Product Features and Benefits - Key features of the FP FleetPro guidance kits include universal compatibility with all brands and models of agricultural machinery, options for hydraulic and electric steering configurations, and user-friendly 10-inch and 12-inch displays [6] - The partnership focuses on reducing input costs, streamlining field operations, and improving crop yields, thereby supporting farmers in enhancing efficiency and productivity [4] Group 3: Availability and Market Reach - The FP FleetPro aftermarket kits are now available through authorized dealerships of Case IH, New Holland, and STEYR across the Europe, Middle East, and Africa (EMEA) region [7] - CHC Navigation operates in over 140 countries and employs more than 2,000 professionals, establishing itself as a leader in the geospatial industry [8]

Core Points - NRx Pharmaceuticals, Inc. will present at NobleCon21 on December 3rd, 2025, focusing on its expanded initiatives in investigational drugs and therapies for mental health conditions [1][2] - The company has begun generating clinical revenue and has made significant advancements in drug development since its last appearance at NobleCon in 2024 [2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in Neuroplastic Therapies for central nervous system disorders, including suicidal depression, PTSD, anxiety, and Autism [5] - The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression and NRX-101 receiving Breakthrough Therapy Designation for suicidal bipolar depression [5] - NRx has filed an Abbreviated New Drug Application for its ketamine formulation, anticipating a launch in July 2026 [5] HOPE Therapeutics Overview - HOPE Therapeutics, a subsidiary of NRx, is establishing a network of interventional psychiatry clinics offering various therapies, including ketamine and transcranial magnetic stimulation [6] - The network is the first in Florida to provide the AMPA One Day (ONE-D) treatment, which combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine for treatment-resistant depression [6] Conference Details - Interested investors can attend the presentation at a discounted rate using a specific discount code [3] - A high-definition video webcast of the presentation will be available on the company's website and other platforms for 90 days following the event [4]

BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern time. The conference is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida. Interested investors and guests o ...

Accelerated start for Ran Narayanasamy as CEO aligns with service rig mobilization at Lawson, multi-well follow-up at Bracken and continued buildout of AI-assisted Large Earth Model Integration (MAXX LEMI) with unparalleled data for Natural Hydrogen covering millions of acres in SaskatchewanNEW Video: Lawson – Canada’s First Big Step into Natural Hydrogenhttps://www.youtube.com/watch?v=lTTOwMxz_zo SASKATOON, Saskatchewan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANK ...

Core Insights - Plug Power Inc. has secured a contract with NASA to supply up to 218,000 kilograms of liquid hydrogen, marking its first supply award from the agency [1][2] - The contract is valued at up to $2.8 million, highlighting Plug's ability to meet NASA's stringent requirements for performance, purity, and reliability [2][5] - This contract positions Plug Power to enter the growing space industry, which presents significant opportunities for liquid hydrogen in the future [2][3] Company Overview - Plug Power is a leader in hydrogen solutions, providing a fully integrated ecosystem that includes production, storage, delivery, and power generation [6] - The company has deployed over 72,000 fuel cell systems and operates 285 fueling stations, making it the largest user of liquid hydrogen [7] - Plug's hydrogen production facilities are operational in multiple states, including Georgia, Tennessee, and Louisiana, with a production capacity of 40 tons per day [7] Strategic Implications - The contract with NASA serves as a strategic springboard for future opportunities in the space sector, demonstrating competitive pricing and reliability in demanding applications [3][5] - Plug's national hydrogen network is proving its capability to meet market needs with reliable, scalable, and lower-carbon supply [3][5] - The award reinforces Plug's long-term strategy to build a hydrogen fuel network that supports various industries, including aerospace and energy systems [5]

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that all rights to Ovaprene®, the company’s first-in-category, investigational, hormone-free monthly intravaginal contraceptive, will be returned to Daré by Bayer HealthCare LLC as a result of Bayer electing to terminate the license agreement between the parties as p ...

Core Points - Sutro Biopharma, Inc. has announced a reverse stock split of its common stock at a ratio of 1-for-10, effective December 3, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 85,193,912 to about 8,519,392 [2] - Proportionate adjustments will be made to the exercise prices and number of shares underlying the Company's outstanding equity awards and incentive plans [2] - No fractional shares will be issued; stockholders entitled to fractional shares will receive shares rounded up to the nearest whole share [3] Group 2: Company Overview - Sutro Biopharma is focused on developing next-generation antibody-drug conjugates (ADCs) aimed at improving cancer treatment [4] - The Company utilizes a cell-free platform to produce ADCs that enhance drug exposure, minimize side effects, and target a broader range of tumor types [4] - Sutro's pipeline includes single- and dual-payload ADCs targeting large oncology markets with significant unmet needs [4]

Core Insights - Rezolve Ai has announced the acquisition of Crownpeak, expected to close within 24 to 48 hours, enhancing its position in the AI economy [1][2] - The integration aims to create a powerful combination of Crownpeak's digital experience platform with Rezolve's Brain Suite, targeting various sectors including Retail, Fashion, and Financial Services [3][6] Financial Overview - The acquisition is valued at approximately $90 million, consisting of $50 million in cash and $33.9 million in equity, while assuming around $150 million in debt [8] - Crownpeak is projected to generate about $70 million in revenue for the current year and is expected to be immediately EBITDA-accretive [7][8] Strategic Implications - This acquisition is part of Rezolve's strategy to consolidate traditional search and discovery platforms, enhancing them with AI capabilities to drive frictionless transactions [5][10] - The deal is anticipated to strengthen Rezolve's recurring revenue base and operational footprint across the US, UK, and EMEA regions [9][11] Product and Technology Integration - The integration of Crownpeak will enable Rezolve to offer advanced AI-driven solutions, including automated sales and intelligent checkout experiences [9][12] - Rezolve's proprietary AI, brainpowa LLM, will be deployed within existing digital infrastructures of enterprise clients, enhancing their operational capabilities [9][12] Market Positioning - The acquisition positions Rezolve as a leader in agentic commerce, combining content, conversation, and conversion in a single AI-driven platform [10][12] - Rezolve aims to capitalize on the growing demand for AI-driven transformation in digital experiences, filling gaps left by legacy digital experience platforms [10][15]

Fort Mill, SC, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced the successful launch of its LockeT suture retention device in Switzerland. The first clinical cases were performed at Spitalzentrum Biel, led by PD Dr. Rainer Zbinden, with excellent procedural outcomes and positive feedback from both the clinical and nursing teams. ...